5-fluorouracil

P3, N=262, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 --> 262 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028

P3, N=89, Completed, Incyte Corporation | Active, not recruiting --> Completed

DPYD rs4294451 T-allele count and male sex were significantly associated with reduced 5-FU drug exposure. DPYD rs4294451 and male sex merit further evaluation as candidate biomarkers to inform initial dosing of infusional 5-FU.

The discovery of rare DPYD variants followed by functional characterization may aid in further optimization of fluoropyrimidine dosing.

P3, N=320, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.

This study investigates the role of nitrogen-doped graphene quantum dots (NGQDs) in enhancing the therapeutic efficacy of 5-fluorouracil (5-FU) in MDA-MB-231 cells under 660 nm diode laser irradiation with 100 mW Laser power...Results showed increased sensitivity of the MDA-MB-231 cells to the 5-FU and decreased ability to maintain redox equilibrium. These findings highlight the crucial role of NGQDs in facilitating triplet state formation and robust ROS generation, ultimately potentiating 5-FU's anticancer efficacy and paving the way for innovative combinational therapies.

P3, N=214, Recruiting, Universität des Saarlandes | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Oct 2025

P2, N=90, Not yet recruiting, Shanghai Zhongshan Hospital

We analyzed outcomes in AGC patients with CPS 1-4 who received nivolumab in combination with capecitabine and oxaliplatin (XELOX) or fluorouracil, oxaliplatin, and leucovorin (FOLFOX) as first-line therapy between April 2021 and December 2024. This real-world retrospective study suggests modest efficacy of AGC patients with low CPS treated with nivolumab with chemotherapy. Further studies are needed to determine the optimal treatment strategy and to identify predictive biomarkers for therapy selection in patients with low-CPS AGC.

Results demonstrated that these phytochemicals exhibited superior binding affinities compared to standard therapy, 5-fluorouracil, with alpha-tocopherol notably outperforming it...Stability assessments showed consistent parameters throughout the simulation. Overall, the prioritized phytochemicals from A. muricata, especially alpha-tocopherol, exhibit significant anticancer potential and stability, supporting further experimental validation and development as therapeutic agents for colon cancer.

Chidamide promoted the sensitivity of GC to 5-FU by suppressing the HDAC3/HNF4A/TYMS axis. This research may provide a foundation for using chidamide to counteract resistance to 5-FU in GC.

The FOX regimen based on 5-fluorouracil (5-FU) and oxaliplatin (OX), a standard therapy for CRC, paradoxically induces both detrimental upregulation of CD47 and beneficial microsatellite instability (MSI). Notably, these effects are achieved at half the FOX dosage with minimal systemic toxicity. This study highlights the potential of nano-immunotherapeutic drugs that function as chemotherapeutic feedback modulators, offering a promising avenue for heterogeneous and immunotherapy-resistant MSS-CRC.